June 22 (Reuters) - Avita Medical Ltd AVH.AX :* FEDERAL COURT OF AUSTRALIA APPROVED SCHEME OF ARRANGEMENT TO EFFECT REDOMICILIATION OF CO TO THE U.S.
June 15 (Reuters) - Avita Medical Ltd AVH.AX :* SHAREHOLDERS VOTED IN FAVOUR OF SCHEME TO EFFECT REDOMICILIATION OF CO
June 5 (Reuters) - Avita Medical Ltd AVH.AX :* GOT CONFIRMATION FROM FIRB COMMONWEALTH HAS NO OBJECTION ON AVITA THERAPEUTICS ACQUIRING CO
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Buy | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 180.78 | 181.60 | 179.00 | +2.180 | +1.22% | 598.17K | Sydney | |||
| 15.75 | 16.23 | 15.52 | +0.410 | +2.67% | 13.26M | Sydney | |||
| 0.02 | 0.00 | 0.00 | 0.000 | 0.00% | 0.00 | Sydney | |||
| 5.80 | 5.88 | 5.70 | +0.16 | +2.84% | 9.79M | Sydney | |||
| 41.17 | 41.48 | 40.57 | +0.58 | +1.43% | 969.44K | Sydney | |||
| 3.98 | 4.00 | 3.955 | +0.030 | +0.76% | 28.20M | Sydney | |||
| 21.27 | 21.70 | 20.04 | +1.48 | +7.48% | 3.61M | Sydney | |||
| 0.23 | 0.00 | 0.00 | 0.000 | 0.00% | 1.64M | Sydney | |||
| 306.26 | 310.76 | 305.51 | -5.75 | -1.84% | 614.76K | Sydney | |||
| 37.72 | 38.34 | 37.72 | 0.000 | 0.00% | 10.86M | Sydney | |||
| 25.46 | 25.64 | 25.37 | +0.210 | +0.83% | 5.13M | Sydney | |||
| 0.61 | 0.00 | 0.00 | -0.025 | -3.94% | 3.37M | Sydney | |||
| 5.70 | 5.70 | 5.65 | +0.02 | +0.35% | 26.57K | Sydney | |||
| 0.086 | 0.00 | 0.00 | 0.000 | 0.00% | 0.00 | Sydney | |||
| 0.175 | 0.00 | 0.00 | 0.000 | 0.00% | 25.92M | Sydney |
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company’s patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient’s own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.